Predictors of Survival in Friedreich's Ataxia: A Prospective Cohort Study.
Friedreich's ataxia
cardiomyopathy
diabetes mellitus
disability stage
survival
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
23 Dec 2023
23 Dec 2023
Historique:
revised:
24
10
2023
received:
15
09
2023
accepted:
27
11
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
aheadofprint
Résumé
Friedreich's ataxia (FA) is a rare multisystemic disorder which can cause premature death. To investigate predictors of survival in FA. Within a prospective registry established by the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS; ClinicalTrials.gov identifier NCT02069509) we enrolled genetically confirmed FA patients at 11 tertiary centers and followed them in yearly intervals. We investigated overall survival applying the Kaplan-Meier method, life tables, and log-rank test. We explored prognostic factors applying Cox proportional hazards regression and subsequently built a risk score which was assessed for discrimination and calibration performance. Between September 2010 and March 2017, we enrolled 631 FA patients. Median age at inclusion was 31 (range, 6-76) years. Until December 2022, 44 patients died and 119 terminated the study for other reasons. The 10-year cumulative survival rate was 87%. In a multivariable analysis, the disability stage (hazard ratio [HR] 1.51, 95% CI 1.08-2.12, P = 0.02), history of arrhythmic disorder (HR 2.93, 95% CI 1.34-6.39, P = 0.007), and diabetes mellitus (HR 2.31, 95% CI 1.05-5.10, P = 0.04) were independent predictors of survival. GAA repeat lengths did not improve the survival model. A risk score built on the previously described factors plus the presence of left ventricular systolic dysfunction at echocardiography enabled identification of four trajectories to prognosticate up to 10-year survival (log-rank test P < 0.001). Arrhythmias, progressive neurological disability, and diabetes mellitus influence the overall survival in FA. We built a survival prognostic score which identifies patients meriting closer surveillance and who may benefit from early invasive cardiac monitoring and therapy. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Friedreich's ataxia (FA) is a rare multisystemic disorder which can cause premature death.
OBJECTIVES
OBJECTIVE
To investigate predictors of survival in FA.
METHODS
METHODS
Within a prospective registry established by the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS; ClinicalTrials.gov identifier NCT02069509) we enrolled genetically confirmed FA patients at 11 tertiary centers and followed them in yearly intervals. We investigated overall survival applying the Kaplan-Meier method, life tables, and log-rank test. We explored prognostic factors applying Cox proportional hazards regression and subsequently built a risk score which was assessed for discrimination and calibration performance.
RESULTS
RESULTS
Between September 2010 and March 2017, we enrolled 631 FA patients. Median age at inclusion was 31 (range, 6-76) years. Until December 2022, 44 patients died and 119 terminated the study for other reasons. The 10-year cumulative survival rate was 87%. In a multivariable analysis, the disability stage (hazard ratio [HR] 1.51, 95% CI 1.08-2.12, P = 0.02), history of arrhythmic disorder (HR 2.93, 95% CI 1.34-6.39, P = 0.007), and diabetes mellitus (HR 2.31, 95% CI 1.05-5.10, P = 0.04) were independent predictors of survival. GAA repeat lengths did not improve the survival model. A risk score built on the previously described factors plus the presence of left ventricular systolic dysfunction at echocardiography enabled identification of four trajectories to prognosticate up to 10-year survival (log-rank test P < 0.001).
CONCLUSIONS
CONCLUSIONS
Arrhythmias, progressive neurological disability, and diabetes mellitus influence the overall survival in FA. We built a survival prognostic score which identifies patients meriting closer surveillance and who may benefit from early invasive cardiac monitoring and therapy. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Banques de données
ClinicalTrials.gov
['NCT02069509']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Commission
ID : HEALTH-F2-2010-242193
Informations de copyright
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Vankan P. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem 2013;126(Suppl. 1):11-20.
Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271(5254):1423-1427.
Yandim C, Natisvili T, Festenstein R. Gene regulation and epigenetics in Friedreich's ataxia. J Neurochem 2013;126(Suppl. 1):21-42.
Lynch DR, Farmer G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal 2021;5(2):NS20200093.
Gonzalez-Cabo P, Palau F. Mitochondrial pathophysiology in Friedreich's ataxia. J Neurochem 2013;126(Suppl. 1):53-64.
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem 2013;126(Suppl. 1):103-117.
Weidemann F, Rummey C, Bijnens B, Stork S, Jasaityte R, Dhooge J, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 2012;125(13):1626-1634.
Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem 2013;126(Suppl. 1):94-102.
Friedreich N. Ueber degenerative Atrophie der spinalen Hinterstränge. Archiv Path Anat Physiol Klin Med 1863;26:391-419. 33-59.
Friedreich N. Ueber Ataxie mit besonderer Berücksichtigung der hereditären Formen. Nachtrag. Virchows Arch Pathol Anat Physiol Klin Med 1877;70:140-152.
Indelicato E, Nachbauer W, Eigentler A, Amprosi M, Matteucci Gothe R, Giunti P, et al. Onset features and time to diagnosis in Friedreich's ataxia. Orphanet J Rare Dis 2020;15(1):198.
Santoro L, De Michele G, Perretti A, Crisci C, Cocozza S, Cavalcanti F, et al. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J Neurol Neurosurg Psychiatry 1999;66(1):93-96.
Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, et al. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol 2015;14(2):174-182.
Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol 2016;3(9):684-694.
Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335(16):1169-1175.
Reetz K, Dogan I, Hilgers RD, Giunti P, Mariotti C, Durr A, et al. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol 2016;15(13):1346-1354.
Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol 2012;27(9):1179-1186.
Schadt KA, Friedman LS, Regner SR, Mark GE, Lynch DR, Lin KY. Cross-sectional analysis of electrocardiograms in a large heterogeneous cohort of Friedreich ataxia subjects. J Child Neurol 2012;27(9):1187-1192.
Tamaroff J, DeDio A, Wade K, Wells M, Park C, Leavens K, et al. Friedreich's ataxia related diabetes: epidemiology and management practices. Diabetes Res Clin Pract 2022;186:109828.
Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011;307(1-2):46-49.
Leone M, Rocca WA, Rosso MG, Mantel N, Schoenberg BS, Schiffer D. Friedreich's disease: survival analysis in an Italian population. Neurology 1988;38(9):1433-1438.
De Michele G, Perrone F, Filla A, Mirante E, Giordano M, De Placido S, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology 1996;47(5):1260-1264.
Pousset F, Legrand L, Monin ML, Ewenczyk C, Charles P, Komajda M, et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol 2015;72(11):1334-1341.
Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354(9177):477-479.
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia; 2023 Available from. https://clinicaltrials.gov/ct2/show/NCT05445323.
Reetz K, Dogan I, Hilgers RD, Giunti P, Parkinson MH, Mariotti C, et al. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol 2021;20(5):362-372.
Hewer RL. Study of fatal cases of Friedreich's ataxia. Br Med J 1968;3(5619):649-652.
Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, et al. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol 2016;79(3):485-495.
Rodden LN, Rummey C, Kessler S, Wilson RB, Lynch DR. A novel metric for predicting severity of disease features in Friedreich's ataxia. Mov Disord 2023;38(6):970-977.
Cunha P, Petit E, Coutelier M, Coarelli G, Mariotti C, Faber J, et al. Extreme phenotypic heterogeneity in non-expansion spinocerebellar ataxias. Am J Hum Genet 2023;110(7):1098-1109.
Rummey C, Corben LA, Delatycki M, Wilmot G, Subramony SH, Corti M, et al. Natural history of Friedreich's ataxia: heterogeneity of neurological progression and consequences for clinical trial design. Neurology 2022;99(14):e1499-e1510.
Eurostat. Mortality and life expectancy statistics; 2023 Available from. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Mortality_and_life_expectancy_statistics.
Ribai P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, Gasparini F, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007;64(4):558-564.
Weidemann F, Liu D, Hu K, Florescu C, Niemann M, Herrmann S, et al. The cardiomyopathy in Friedreich's ataxia - new biomarker for staging cardiac involvement. Int J Cardiol 2015;194:50-57.
Mejia E, Lynch A, Hearle P, Okunowo O, Griffis H, Shah M, et al. Ectopic burden via Holter monitors in Friedreich ataxia. Pediatr Neurol 2021;117:29-33.
Payne RM. Cardiovascular research in Friedreich ataxia: unmet needs and opportunities. JACC Basic Transl Sci 2022;7(12):1267-1283.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145(18):e895-e1032.
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018;379(20):1977.
St John Sutton M, Ky B, Regner SR, Schadt K, Plappert T, He J, et al. Longitudinal strain in Friedreich ataxia: a potential marker for early left ventricular dysfunction. Echocardiography 2014;31(1):50-57.
Danaei G, Lu Y, Singh GM, Carnahan E, Stevens GA, Cowan MJ, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2014;2(8):634-647.
Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol 2018;17(4):327-334.
Corben LA, Collins V, Milne S, Farmer J, Musheno A, Lynch D, et al. Clinical management guidelines for Friedreich ataxia: best practice in rare diseases. Orphanet J Rare Dis 2022;17(1):415.
Norrish G, Rance T, Montanes E, Field E, Brown E, Bhole V, et al. Friedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Arch Dis Child 2022;107(5):450-455.
Friedreich's Ataxia Integrated Clinical Database (FA-ICD); Available from https://c-path.org/programs/rdca-dap/.